{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-24-000071","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2024-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.438877+00:00","generated_at":"2026-05-31T13:22:56.086434+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exagen appoints Jeffrey Black as CFO; Kamal Adawi steps down","bullets":["Jeffrey G. Black named CFO effective Sept 1, 2024; replaces Kamal Adawi.","John Aballi serves as interim CFO from July 31 until Black's start.","Black receives $460K base salary, $125K signing bonus, and up to 225K RSUs.","Black previously CFO at Standard BioTools, Apollo Endosurgery, and Alphatec Spine.","Adawi entitled to severance as Tier 2 participant under company's severance plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-24-000071","json":"https://secwatch.observer/filing/0001274737-24-000071.json","markdown":"https://secwatch.observer/filing/0001274737-24-000071.md","text":"https://secwatch.observer/filing/0001274737-24-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000071/0001274737-24-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000071/exdx-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:22:56.086434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"405f6ad059","claim":"Jeffrey Black was appointed as Chief Financial Officer at EXAGEN INC..","evidence_excerpt":"On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000071/0001274737-24-000071-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"678e9eaf6c","claim":"Kamal Adawi departed as Chief Financial Officer and Corporate Secretary at EXAGEN INC..","evidence_excerpt":"On July 31, 2024, the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of July 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000071/0001274737-24-000071-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"no longer serves"},{"label":"Role","value":"Chief Financial Officer and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"87a46d60c7","claim":"John Aballi was appointed as Interim Chief Financial Officer at EXAGEN INC..","evidence_excerpt":"John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000071/0001274737-24-000071-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}